- Incretin mimetics, a class of antidiabetic medications including GLP-1 receptor agonists and GIP/GLP-1 dual agonists, are increasingly becoming vital components in modern diabetes management due to their ability to regulate blood glucose levels, promote weight loss, and offer cardiovascular benefits. Their integration into treatment plans for type 2 diabetes reflects growing clinical confidence and patient acceptance
- The escalating demand for incretin mimetics is primarily driven by the rising global prevalence of type 2 diabetes, increasing awareness of metabolic health, and the shift toward combination therapies that improve patient outcomes while minimizing adverse effects
- North America dominated the incretin mimetics market with the largest revenue share of 39.70% in 2024, fueled by early adoption of novel diabetic treatments, robust healthcare infrastructure, favorable reimbursement policies, and high levels of obesity and diabetes incidence in the U.S. The region continues to witness strong growth, especially with the approval of advanced GLP-1/GIP dual receptor agonists
- Asia-Pacific is expected to be the fastest-growing region in the incretin mimetics market during the forecast period, with a projected CAGR of 12.5%, driven by increasing urbanization, rising disposable incomes, growing healthcare access, and a surge in diabetes prevalence in populous countries such as China and India
- The diabetes segment dominated the incretin mimetics market, capturing a market share of 81.5% in 2024, driven by the high global prevalence of type 2 diabetes and the proven efficacy of incretin-based therapies in glycemic control and weight management
